
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
Let’s start with the continued — and very necessary — push to develop medicines and vaccines against the novel coronavirus. There has already been a lot written about the experimental mRNA-based vaccine Moderna is developing, for which it currently hasn’t disclosed specific data. That should change relatively soon with the publication of the Phase 1 study results in a scientific journal.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.